Introduction
Programmed cell death (PCD) plays an indispensable role in the maintenance of homeostasis in normal tissues, and probably contributes to cancer cell expansion when rates of cell losses are insufficient to offset new cell production caused by mitosis. 1 Non-Hodgkin's lymphomas (NHL) represent a heterogeneous spectrum of neoplasms, in which distinct subtypes can be defined by clinical, histological, immunophenotypical, cytogenetic, and molecular genetic features. 2 Alteration of the PCD genetic pathway was demonstrated to play a central role in the development of NHLs belonging to the follicular subtype, which harbor the t(14;18) translocation, a chromosomal rearrangement which involves the Bcl-2 gene. 3, 4 The ability of Bcl-2 to impact on some, but not all, apoptotic pathways, has led to the discovery of other gene products regulating PCD, 1 which have been included in a 'Bcl-2 family' on the basis of structural homologies in the conserved BH1, BH2 and BH3 domains of Bcl-2. Some Bcl-2-homologues, like Bax, 5 Bad, 6 Bak 7 and Bcl-xS, 8 accelerate PCD, whereas others, like Bcl-xL, 8 Mcl-1 9 and Bag-1, 10 possess anti-PCD activity. These various proteins are often capable of competitive heterodimerization with Bcl-2. 11 It was previously proposed that the decisional setpoint of PCD is governed by the ratio of death antagonists to death agonist molecules. 12 Recent reports suggest that despite the existence of in vivo competition between Bax and Bcl-2, each of them is able to regulate apoptosis independently. 13 The main members of the Bcl-2 family, like Bcl-2, Bax and Bcl-x, were shown to act as pore forming molecules; they can create ion channels in lipid bilayers. 14, 15 However, the mechanism(s) by which the proteins of the Bcl-2 family regulate PCD is still unknown.
It is usually possible to predict the outcome of NHL patients on the basis of histological classifications, 16, 17 but additional prognosis markers, cytogenetic or molecular, would be helpful. The expression of members of the Bcl-2 family, either alone or in combination, assessed by immunohistochemistry (IHC) was evaluated as such a marker. Thus, association of Bcl-2 positivity with poor prognosis was demonstrated in patients with diffuse large cell lymphoma (DLCL). 18 In contrast, no significant correlation between Bax expression and prognosis could be demonstrated. 19 Both the actual frequency and the levels of expression of PCD regulators in NHLs is yet undetermined, since the threshold level of sensitivity of IHC is highly related to the tissue fixation process, which can damage proteins. Western blotting (WB) was used as an alternative method to quantitate the expression of Bcl-2 homologs in lymphoproliferations like acute leukemia 20, 21 and chronic lymphocytic leukemia (CLL); [22] [23] [24] the relative levels of Bax and Bcl-2 expression were thus shown to be correlated with the apoptotic sensitivity of CLL cells, 22 but other studies showed no correlation between drug sensitivity and Bax and Bcl-2 levels in CLL cells. 23 We have postulated that expression levels of PCD regulators may contribute to the clinicopathological heterogeneity between NHL subtypes. To check this hypothesis, the levels of expression of several PCD regulators were quantified by WB in a panel of biopsy samples from various subtypes of B-NHLs.
Materials and methods

Tissue sampling
Fresh tumor biopsy specimens representative of the various subtypes of human B cell NHLs were obtained from 33 patients. Case distribution according to the revised EuropeanAmerican classification (REAL) of lymphoid neoplasms 2 was as follows: nine small lymphocytic (SLL), eight mantle cell (MCL), eight follicular (FL), and eight diffuse large cell (DLCL) NHLs (Table 1) . A portion of each sample was submitted to conventional histopathological processing and standard immunophenotyping. The other part was gently teased in RPMI 1640 medium. Samples were directly included in the study without further purification when the malignant clone represented more than 98% of the total population of B cells, as evaluated by the exclusive detection of or light chains (Dakopatts, Glostrup Denmark) by flow cytometry. Three samples of reactive lymph nodes and tonsil were included as controls.
Purification of B cells from fresh lymphoma tissues
Malignant or reactive B cells from tissue samples were separated using either magnetic beads conjugated with anti-CD19 mAbs (Immunotech, Marseille, France), as described, 25 or a standard rosetting technique using 2-aminoethyl-isothiouronium bromide (AET)-sensitized sheep red blood cells, as described. 26 The isolated B cell populations, analyzed by flow cytometry on a FACScan, were uniformly Ͼ95% CD20 + and Ͻ5% CD3 + ; their monoclonality was checked by the exclusive detection of or light chains (Dakopatts). B cells were then either immediately used for preparation of protein lysates or cryopreserved.
Western blot (WB) analysis
1×10
6 cells, harvested from cell suspensions, were added to lysis buffer (10 mm Tris-HCl pH 7.4, containing 1% SDS and 1 mm sodium vanadate), and heated in a microwave oven for 10-15 s. Protein lysates were separated by 7.5% SDS-PAGE and transferred to Immobilon-P membranes (Millipore, Bedford, MA, USA) as recommended by the manufacturer. Membranes were probed with the following antibodies: antiBcl-2 monoclonal antibody (mAb) (Dakopatts), anti-Bax mAb (Immunotech), anti-Bad mAb (Transduction Laboratories, Lexington, KY, USA), anti-Bag-1 polyclonal antibody (Calbiochem, Cambridge, MA, USA), anti-Bcl-x and anti-Bak polyclonal antibodies (kindly provided by Dr JC Reed, La Jolla Cancer Research Foundation, La Jolla, CA, USA). Development was performed with the enhanced chemiluminescence system (ECL, Amersham, Bucks, UK).
Quantification of protein expression
To ensure that the levels of expression of the various proteins could be compared between different samples, (1) equal cell numbers were loaded on the gels, (2) duplicate gels were stained with Coomassie blue, as an additional loading control, and (3) every blot was reprobed with a polyclonal antibody (Upstate Biotechnology, Lake Placid, NY, USA), directed against the p 85 subunit of phosphatidyl-inositol-3-OH kinase (P13K), which is known to display a uniform level of expression among lymphoid tissues. 27, 28 Band intensity was quantified by densitometry using a Biolmage analyzer (Biolmage, Palo Alto, CA, USA). Normalized level of expression of a specific protein was given as the ratio (optical density of the specific protein/optical density of p 85), and standardized results were expressed in arbitrary units. Expression levels and ratio to p 85 were calculated from at least two independent determinations.
Statistical analysis
The Kruskall-Wallis test was used to determine the existence of a significant difference in expression levels between histological groups (P = 0.04 for threshold value of significance). When appropriate, the non-parametric Mann-Whitney U test was used (P = 0.01 for threshold value of significance).
Results
Results are summarized in Table 1 and Figure 1 .
Anti-apoptotic agents Bcl-2 expression:
In the three normal B cell samples, the anti-Bcl-2 mAb detected a protein of 26 kilodaltons (kDa), the predicted molecular weight of Bcl-2, 3,4 with a mean nor-
Figure 1
Expression levels of apoptosis regulatory proteins in NHL subtypes. Expression levels are represented as point diagrams. Each point corresponds to a case. Histological types are indicated on the horizontal axes. Vertical axes indicate the normalized expression levels of the respective apoptotic regulatory molecules as the ratio (densitometric value of Western blot band using specific antibody/densitometric value of Western blot band using anti-p 85/P13K antibody). For a specific apoptotic regulator, wide variations of expression levels can be generally observed between the different histological subtypes and cases within each subtype. However, a few significant differences, such as a lower expression of Bak in FLs compared to other NHL subtypes, can be suspected prior to statistical analysis. malized intensity level of 1.7. All the 33 NHL cases displayed a positive Bcl-2 signal by WB (Figures 1 and 2) . Quantification showed that the highest levels were observed in the FL and MCL groups (mean values: 2.4 and 1.9, respectively), with wide variations between the different samples in both groups (Standard deviation (s.d.): 1.4 and 1.0, respectively). In the DLCL and SLL groups, expression levels were lower (mean values: 1.6 and 1.7, respectively), and were more homogeneous within the SLL group than within the DLCL group (s.d.: 0.6 and 1.3, respectively). The Kruskal-Wallis test did not show a significant statistical difference (P = 0.429) between the histological groups.
Bcl-xL expression:
The polyclonal anti-Bcl-x antibody detected two proteins in normal B cells, with apparent molecular weights of 29 and 17 kDa, corresponding to Bcl-xL and Bcl-xS, respectively. 8 The mean normalized level was 0.8 for Bcl-xL. All the 33 NHL cases displayed a positive Bcl-xL signal by WB (Figures 1 and 2) . Signal intensities were relatively homogeneous within the SLL and FL groups (s.d.: 1.0 and 0.3, respectively), and more heterogeneous in the DLCL and MCL groups (s.d.: 2.3 and 2.6, respectively). Although there was a tendency for a lower expression in FL, no significant statistical correlation was found using the Kruskal-Wallis test (P = 0.121).
Bag-1 expression:
Expression of the Bag-1 protein was detected by WB as a 29 kDa band in normal B cells and in all the 33 NHL cases analyzed (Figures 1 and 2 ). Mean value was 0.8 in normal samples. Signals were weak and homogeneous in the SLL, MCL and FL groups (mean values: 0.1, 0.5, and 0.6, respectively), and higher in the DLCL group (mean value: 1.2). A significant statistical difference was observed between the SLL and FL groups using the MannWhitney test (P = 0.0004).
Pro-apoptotic agents Bax expression:
The anti-Bax mAb detected a protein of 21 kDa in normal B cells, corresponding to the p 21 Bax-␣ isoform, 3 with a normalized mean level of 1.8. Bax expression was detected in all the 26 NHL cases analyzed (Figure 2 ). Few variations were observed between the MCL, FL and SLL groups (mean values: 1.0 for all groups), and within each group. The DLCL group displayed a relatively high mean value (1.5); this difference was not significant using the Kruskal-Wallis test (P = 0.906).
Bcl-xS expression:
In the three samples of normal B cells, the Bcl-xS band displayed a normalized level of 1. A Bcl-xS band was observed in the 33 NHL cases analyzed by WB (one case could not be analyzed by densitometry) (Figures 1 and  2 ). Slight variations in signal intensities were observed between the different groups (mean values: 1.5 for SLL, 2.2 for MCL, 1.1 for FL and 1.4 for DLCL). Variations within the SLL and FL groups were close to those observed for Bcl-xL (s.d.: 0.8 and 0.2, respectively), whereas variations within the MCL and DLCL groups were slightly less important than for Bcl-xL (s.d.: 1.5 and 1.1, respectively). The Kruskal-Wallis test did not show a significant statistical difference between the histological groups (P = 0.556).
Bad expression:
The Bad protein was detected as a 23 kDa band in the 30 NHL cases as in control normal B cells (Figures 
Bak expression:
The Bak protein was detected by WB as a 30 kDa band in the 28 NHL cases analyzed and in normal B cells (Figures 1 and 2 ). Mean intensity level was 0.5 in normal samples. Signals were uniformly weak in the SLL, MCL and FL groups (mean values: 0.4, 0.3 and 0.1, respectively), and higher in the DLCL group (mean value: 0.7). The Mann-Whitney test showed that differences were significant between the FL group and the other groups (SLL, P = 0.0004; MCL, P = 0.00035; DLCL, P = 0.002).
Discussion
This report describes the expression profiles, in NHLs, of the major members of the Bcl-2 family of apoptotic regulators, using a quantitative immunoblotting approach, an investigation until now not reported. In previous IHC studies, Bcl-2, Bcl-x, Bax and Mcl-1 were shown to be expressed in some NHL samples, but their levels of expression could not be quantified. 18, 19, 29 Bcl-2 and the panel of six homologues tested were found to be expressed in 100% of the NHLs, although at varying levels. These results indicate that molecules of the Bcl-2 family are more widely expressed in NHLs than suggested by previous IHC studies, in which a significant number of samples were negative. 18, 19, 29 In addition, our data show for the first time that the Bak, Bag-1 and Bad molecules are expressed in NHLs. The increased sensitivity of WB compared to IHC, in which target epitopes are likely subject to alterations during the tissue fixation process, may largely account for this unexpected ubiquitous expression profile.
Both normal B cell samples and NHL cases expressed simultaneously pro-apoptotic proteins, Bax, Bcl-xS, Bak and Bad, and anti-apoptotic proteins, Bcl-2, Bcl-xL and Bag-1. Nonetheless, when compared to all NHL samples, normal B cells expressed a higher mean level of Bax (1.8 vs 1.1) and a lower level of Bcl-xL (0.9 vs 2.3). This may explain, on the one hand, the relative sensitivity of normal B cells to Fas-induced cell death, 30 and on the other hand, the enhanced cell survival of NHL cells. 25, 26 This hypothesis remains speculative, since the effect resulting from accumulation of antagonist apoptotic regulators is hazardous to predict, as the effect of Bcl-2 homologues is determined not only by their expression levels, but also, and more importantly, by their capacity to heterodimerize. [11] [12] [13] Finally, one cannot exclude the influence of other, yet unidentified, or newly described members of the Bcl-2 family, such as Bcl-x␥. 31 Levels of Bcl-2 expression in the FL cases we tested were not significantly different from the levels observed in other NHL types. This finding, although in accordance with the Bcl-2 immunostaining frequently detected by IHC in non-follicular NHLs such as DLCL and MCL, 18 appears paradoxical. The classical cause of Bcl-2 overexpression in FL, namely the t(14;18), is usually not found in other NHL subtypes, and occurs in only 20-40% of DLCL cases. 2 High levels of Bcl-2 expression, in the absence of a t(14;18), point to the existence of alternative pathways of deregulation of Bcl-2 expression in non-follicular NHLs. External signals such as interferons, 32 IL-4, 33 adhesion molecules 34 and CD40, 35 may play a role in promoting high levels of Bcl-2 expression.
Expression of Bad in NHL cases is paradoxical, since it was detected by IHC in normal plasma cells, but almost never in normal lymphocytes. 36 The weak intensity of Bad signals in WB experiments suggests that expression levels are low and likely to be below the threshold level of IHC sensitivity, in accordance with the previous detection of low amounts of the Bad protein in hematopoietic and lymphoid cell lines. 36 The significantly higher expression of Bad in the DLCL subtype, when compared with the FL and MCL groups, may be implicated in the particular sensitivity of DLCL cells to spontaneous PCD. 25, 26 In contrast with FL and MCL, most DLCL cases morphologically display a higher number of mitoses and apoptotic figures, 2,16,17 a feature which could be related to their overexpression of Bad. In a similar manner, the relatively lower Bak expression in FL compared to DLCL may contribute to the lower propensity of FL to spontaneous PCD, observed by both histological and functional analysis. 2, 16, 17, 25, 26 The significant differences in Bak and Bag expression observed between FL and SLL is more difficult to explain from either a morphological or a functional standpoint.
We previously reported that cells from the different B-NHL subtypes were more resistant to Fas-mediated PCD 25, 26 than normal B cells. The present report suggests a specific antiapoptotic role of Bcl-xL in the apoptotic resistance of lymphoma cells, as we observed a lower level of Bcl-xL in normal B-cells, in accordance with our previous report. 37 Increased Bcl-xL levels were also reported in FL cells which survive upon CD40 stimulation. 38 Bax expression levels may be also an important parameter, as we found a significant difference between NHL cells and normal B cells.
In conclusion, variations in the levels of Bcl-2 family apoptotic regulators are partly correlated to NHL subtyping and may contribute to some of their pathological features. As the significance of some of the variations remains unclear, additional alterations of the PCD pathway are likely to occur in NHL cells to enhance their survival. Further studies should focus on analyzing the integrity of the molecules and mechanisms transmitting signals from Fas to apoptotic effectors such as caspases.
